Search

Your search keyword '"Neelakantan, Pratap"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Neelakantan, Pratap" Remove constraint Author: "Neelakantan, Pratap"
31 results on '"Neelakantan, Pratap"'

Search Results

1. Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm

2. Optimisation of CML therapy

3. Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline.

5. sj-docx-2-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

6. sj-docx-3-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

7. sj-docx-1-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

8. sj-docx-4-tah-10.1177_20406207221084487 – Supplemental material for A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

9. A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

10. Low Incidence of COVID-19 Infection in Patients with Acute Myeloid Leukemia Undergoing Reduced Intensity/Venetoclax Based Treatment: Initial Results of the PACE Prospective Clinical Study from the UK Trials Acceleration Program

13. Contributors

16. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy

17. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

19. A Retrospective Real-World Study of the Current Treatment Pathways for Myelofibrosis in the UK (The REALISM UK Study)

20. Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

21. Breast cancer metastasizing to the tongue

23. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.

24. Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.

27. Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects

29. Can the Combination of the Measurement of BCR-ABL1 Transcript Levels At 3 and 6 Months Improve the Prognostic Value of the 3 Month Measurement?

30. The management of myelofibrosis: A British Society for Haematology Guideline.

31. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.

Catalog

Books, media, physical & digital resources